Attune Pharmaceuticals Announces $23M Series B Financing to Advance ATN-249 for the Treatment of HAE
Attune Pharmaceuticals Announces Positive Phase 1 Results for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE
Attune Pharmaceuticals Announces Positive Data from Recent Pre-Clinical Studies for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at C1-INH Deficiency Workshop
Attune Pharmaceuticals Announces Pre-Clinical Data for ATN-249, An Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at AAAAI
Attune Pharmaceuticals Announces Late-Breaking Poster Presentation of ATN-249, an Oral Kallikrein Inhibitor for the Treatment of HAE
Pharmacokinetics, Safety, Pharmacodynamics, and Potency of ATN-249, a Novel Oral Plasma Kallikrein Inhibitor for Hereditary Angioedema
11th C1-inhibitor Deficiency and Angioedema Workshop
Pharmacokinetics and Safety of ATN-249, a Novel Oral Plasma Kallikrein Inhibitor for Hereditary Angioedema
Safety Study of ATN-249, A New Oral Kallikrein Inhibitor for Hereditary Angioedema
Selectivity, Potency, and Exposure Evaluation of ATN-249, A New Oral Kallikrein Inhibitor for Hereditary Angioedema